The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change? Clin Transl Radiat Oncol 2021 May;28:124-128
Date
05/14/2021Pubmed ID
33981865Pubmed Central ID
PMC8085778DOI
10.1016/j.ctro.2021.04.002Scopus ID
2-s2.0-85104326512 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited to the tumor, and should consider hypofractionated approaches to regional nodes.